证券代码：002166 证券简称：莱茵生物 1 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2022-016 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n 其他 电话交流会 | □分析师会议 \n 业绩说明会 \n□路演活动 | | 参与单位名称及 | 参会机构名单详见附件 | | | 人员姓名 | | | | | | | | 时间 | 2022 年 10 月 25 日 | | | 地点 | 公司会议室 | | | | 副总经理兼董事会秘书 | 罗华阳先生 | | 上市公司接待人 | 财务总监 | 郑 辉女士 | | 员姓名 | 证券事务代表 | 王庆 ...

Revenue and Profitability - Revenue for Q3 2022 reached ¥337,136,268.94, an increase of 29.97% year-over-year, and year-to-date revenue was ¥978,883,646.66, up 37.44% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥42,480,485.91, representing a 51.87% increase year-over-year, with a year-to-date net profit of ¥175,812,920.45, up 100.71%[3] - Basic earnings per share for Q3 2022 was ¥0.07, a 40.00% increase, while diluted earnings per share also stood at ¥0.07, reflecting the same growth[3] - The company's total revenue for the first three quarters of 2022 reached CNY 978.88 million, a 37.44% increase compared to CNY 712.25 million in the same period of 2021, driven by strong demand in the plant extraction market[19] - Net profit attributable to shareholders of the parent company was CNY 175,812,920.45, up 100.5% from CNY 87,597,659.59 year-on-year[35] - Operating profit for the period was CNY 245,930,427.56, representing a significant increase from CNY 111,320,546.71 in the previous year[35] Assets and Equity - Total assets as of September 30, 2022, amounted to ¥4,451,645,750.27, a 36.60% increase from the previous year-end[4] - Shareholders' equity reached ¥3,064,802,739.15, marking a significant increase of 64.01% compared to the previous year-end[4] - The company's total equity attributable to shareholders of the parent company increased to CNY 3,064,802,739.15 from CNY 1,868,651,254.39[34] - Total assets increased to RMB 4,451,645,750.27 as of September 30, 2022, up from RMB 3,259,000,827.99 at the beginning of the year[32] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥133,200,628.82, showing a decrease of 25.55% compared to the previous year[3] - The company reported a net cash flow from financing activities of CNY 1.04 billion, a remarkable increase of 882.33% from a net outflow of CNY 132.60 million in the same period last year, primarily due to funds raised from a private placement[15] - Cash inflow from operating activities amounted to CNY 1,059,595,375.87, an increase from CNY 800,589,857.40 in the previous year[36] - The cash inflow from financing activities reached ¥1,567,806,472.25, significantly higher than ¥448,316,262.17 in Q3 2021, leading to a net cash flow from financing activities of ¥1,037,369,130.36[37] Investments and Expenditures - The company plans to invest up to RMB 730,000,000 in its wholly-owned subsidiary for the construction of a specialized stevia extraction factory, with RMB 50,000,000 allocated to registered capital[28] - The company’s investment activities resulted in a net cash outflow of CNY 267.11 million, a 288.04% increase in outflow compared to the previous year, mainly due to participation in Guilin Bank's share placement[15] - The total cash outflow from investing activities was ¥289,146,987.74, compared to ¥144,370,044.49 in the previous year, resulting in a net cash flow from investing activities of -¥267,109,083.21[37] Research and Development - Research and development expenses increased by 40.31% to CNY 35.37 million from CNY 25.21 million, reflecting higher investment in R&D during the reporting period[19] - Research and development expenses rose to CNY 35,365,974.87, up from CNY 25,206,415.86 in the previous year, indicating a focus on innovation[34] Other Financial Metrics - The company’s net asset return rate was 1.78% for Q3 2022, reflecting a slight increase of 0.25% compared to the previous year[3] - The company’s weighted average return on equity rose to 8.40%, an increase of 3.59% compared to the previous year[20] - The company reported a significant increase in other comprehensive income, totaling CNY 59,228,633.19, compared to a loss of CNY 3,380,440.22 in the same quarter last year[35] Legal and Compliance - The company faced a lawsuit resulting in a potential liability of approximately USD 1.33 million, impacting net profit by about RMB 17.83 million[30] - The report for Q3 2022 was not audited, which may affect the perception of financial reliability[39] Cash and Cash Equivalents - The company reported a cash balance of RMB 994,164,870.52 as of September 30, 2022, compared to RMB 97,411,157.55 at the beginning of the year[31] - The net cash and cash equivalents increased by 4,035.99% to CNY 905.09 million, primarily due to the funds received from the private placement[15] - The total cash and cash equivalents at the end of Q3 2022 amounted to ¥968,033,105.23, up from ¥119,043,168.43 at the end of Q3 2021[37]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 641,747,377.72, representing a 41.71% increase compared to CNY 452,859,694.68 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 133,332,434.54, a significant increase of 123.62% from CNY 59,625,618.14 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 112,368,161.93, up 218.97% from CNY 35,228,284.21 year-on-year[20]. - The basic earnings per share increased to CNY 0.24, reflecting an increase of 118.18% compared to CNY 0.11 in the same period last year[20]. - The total operating revenue for the reporting period reached CNY 641,747,377.72, representing a year-on-year increase of 41.71% compared to CNY 452,859,694.68 in the same period last year[66]. - The total comprehensive income for the first half of 2022 was ¥165,263,094.82, compared to ¥59,338,639.80 in the same period of 2021, indicating a growth of 178.5%[170]. - The company reported a net profit margin improvement, with net profit for the first half of 2022 showing a positive trend compared to the previous year, although specific figures were not disclosed[168]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,300,984,136.23, a 1.29% increase from CNY 3,259,000,827.99 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were CNY 2,028,012,957.22, which is an 8.53% increase from CNY 1,868,651,254.39 at the end of the previous year[20]. - Total liabilities decreased to CNY 1.23 billion in the first half of 2022 from CNY 1.36 billion at the beginning of the year, representing a reduction of 9.2%[162]. - The company's equity attributable to shareholders increased to CNY 2.03 billion as of June 30, 2022, compared to CNY 1.87 billion at the beginning of the year, marking an increase of 8.5%[162]. Cash Flow - The net cash flow from operating activities was CNY 82,111,639.72, a decrease of 19.82% compared to CNY 102,414,666.24 in the same period last year[20]. - The cash flow from operating activities for the parent company was CNY 110,246,648.20, up 72.5% from CNY 63,876,694.99 in the same period last year[177]. - The net cash flow from investing activities was negative at CNY -43,080,720.94, compared to a positive CNY 4,066,454.61 in the first half of 2021[176]. - Cash inflow from financing activities totaled CNY 383,545,205.00, a significant increase from CNY 292,695,429.90 in the same period last year[176]. Business Operations - The natural sweetener business generated revenue of 388.41 million yuan, marking a growth of 47.09% year-on-year, and became the core driver of the company's performance[28]. - The company achieved total revenue of 641.75 million yuan in the first half of 2022, representing a year-on-year growth of 41.71%[28]. - The company has established a strategic partnership with Firmenich, achieving sales of 37.93 million USD, a growth of 32.06% year-on-year, with future orders expected to reach approximately 188.72 million USD[29]. - The company is in the process of a non-public offering to establish a specialized extraction factory with an annual capacity of 4,000 tons of stevia, aimed at enhancing production capacity and reducing costs[29]. Research and Development - Research and development investment totaled 24.88 million yuan, up 64.56% from the previous year, with a total of 114 patents held[30]. - The company has established long-term collaborations with numerous universities and research institutions to enhance its R&D capabilities and accelerate product and process development[62]. - The company is focusing on innovation in plant extracts for animal feed, responding to regulatory changes and market demand for safer alternatives[39]. Market Trends and Risks - The global market for natural sweeteners, particularly steviol glycosides, is projected to reach $1.17 billion by 2026, driven by increasing health consciousness and demand for sugar alternatives[35]. - The ongoing COVID-19 pandemic poses risks to product transportation and operations, but the company is adapting by expanding online communication and ensuring timely product delivery[88]. - The plant extraction industry faces market risks due to incomplete domestic regulations and potential competition from new entrants, with a focus on maintaining high-quality products and strong customer relationships[89]. Corporate Governance and Strategy - The company has a governance structure that includes a shareholders' meeting, board of directors, and supervisory board[195]. - The company is committed to reducing reliance on major clients by diversifying its product offerings and expanding market share in other product categories[91]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[181].

桂林莱茵生物科技股份有限公司 2022 年第一季度报告全文 证券代码：002166 证券简称：莱茵生物 公告编号：2022-029 桂林莱茵生物科技股份有限公司 2022年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3、第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 282,409,086.05 | 221,038,586.19 | 27.76% | | 归属于上市公司股东的净利润（元） | 38,424,186.65 | 21,5 ...

Financial Performance - The company's operating revenue for 2021 was ¥1,053,235,426.39, representing a 34.40% increase compared to ¥783,671,413.74 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥118,438,152.08, a 37.74% increase from ¥85,989,396.92 in 2020[20]. - The net profit after deducting non-recurring gains and losses was ¥85,345,120.37, which is a 58.95% increase from ¥53,693,065.83 in 2020[20]. - The company's cash flow from operating activities showed a significant decline, with a net cash flow of ¥26,240,101.96, down 87.11% from ¥203,583,341.85 in 2020[20]. - The total assets at the end of 2021 were ¥3,259,000,827.99, reflecting a 3.05% increase from ¥3,162,557,184.02 at the end of 2020[21]. - The net assets attributable to shareholders increased by 4.37% to ¥1,868,651,254.39 at the end of 2021, compared to ¥1,790,411,360.98 at the end of 2020[21]. - The company reported a basic earnings per share of ¥0.21 for 2021, a 40.00% increase from ¥0.15 in 2020[20]. - The weighted average return on equity for 2021 was 6.48%, up from 4.86% in 2020[20]. - The company achieved total operating revenue of 1,053.24 million yuan in the reporting period, representing a year-on-year growth of 34.40%[73]. - The natural sweetener business generated revenue of 633.57 million yuan, a year-on-year increase of 54.86%, accounting for 60.15% of total revenue[73]. - The plant extraction segment reported revenue of 1,015.26 million yuan, with a year-on-year growth of 55.64%[73]. - The tea extraction business generated revenue of 188.43 million yuan in 2021, with tea extraction contributing 163.65 million yuan, representing 15.54% of the company's total revenue[98]. Business Strategy and Operations - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[5]. - The company emphasizes the importance of understanding risks such as policy, market, raw material procurement, technology, and financial risks[4]. - The company has established several wholly-owned subsidiaries, including LAYN USA and LAYN EUROPE[12]. - The company aims to become the most trusted provider of natural health products and services globally[62]. - The company is focused on the extraction of functional plant ingredients, catering to various industries including food, beverage, and cosmetics[63]. - The company has established partnerships with numerous universities and research institutions to enhance its R&D capabilities and promote technology transfer[79]. - The company emphasizes a "cost leadership" strategy to enhance labor productivity and control production costs through organizational optimization and equipment upgrades[70]. - The company is actively developing new products, with five projects underway, including two that have entered trial production[123]. - The company plans to enhance communication with clients and suppliers to mitigate the adverse effects of the pandemic, while also improving product quality and reducing costs through technological advancements[168]. Market Trends and Industry Insights - The plant extraction industry is experiencing growth, with China's exports of plant extracts reaching 96,000 tons in 2020, a year-on-year increase of 11.0%[32]. - The natural sweetener industry is experiencing rapid growth due to increasing consumer awareness of health risks associated with excessive sugar intake, leading to a global focus on "sugar reduction" and "sugar control"[33]. - The global market for steviol glycosides is projected to exceed $1.6 billion by 2028[37]. - The demand for low-sugar and no-sugar products is rapidly increasing, with consumers showing a preference for natural sweeteners over synthetic ones[44]. - The market for tea polyphenols, a key component in tea extracts, has broad applications in food, pharmaceuticals, and daily consumer products due to its health benefits[52]. - The functional food market in China grew from 114 billion yuan in 2012 to 358.6 billion yuan in 2019, with a compound annual growth rate of 17.8%[58]. - The company expects the plant extraction industry to experience rapid growth driven by increasing consumer demand for natural and healthy products[152]. Research and Development - The company has successfully developed over 300 standardized plant extract products, including monk fruit extract and tea extract[63]. - The company increased its R&D investment to 38.98 million yuan in 2021, a 62.12% increase year-on-year, resulting in the development of three new stevia-related products and 15 plant extraction R&D projects[99]. - The company has established a robust internal control system to enhance governance and compliance with regulations[181]. - The company is committed to capital operations and seeks investment and acquisition opportunities that align with its strategic goals[160]. - The company will continue to develop its research capabilities to support consumer brands and enhance customer service[161]. Governance and Management - The company has established a complete governance structure including a shareholders' meeting, board of directors, and supervisory board, ensuring independent decision-making[190]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements[182]. - The company has independent financial management systems and does not share bank accounts with controlling shareholders[189]. - The company emphasizes the importance of independent directors in providing professional advice to the board[183]. - The company has not faced any penalties from securities regulatory agencies for its current or recently departed directors and supervisors[197]. Risks and Challenges - The company faces potential policy risks related to food safety regulations and the evolving legal landscape for industrial hemp[165]. - The COVID-19 pandemic has increased market volatility, with nearly 70% of the company's revenue and industrial hemp projects coming from international markets, making them vulnerable to global economic fluctuations[167]. - The company relies on natural raw materials like monk fruit and stevia, which are subject to supply risks due to seasonal and regional factors, impacting production costs and availability[170]. - The company has seen an increasing reliance on its top five customers, prompting a strategy to diversify its client base and expand product offerings to reduce dependency[172]. - The company faces technology risks in the fast-evolving natural extraction industry, necessitating continuous R&D investment and talent acquisition to maintain a competitive edge[173]. Cash Flow and Financial Management - Operating cash inflow totaled approximately ¥1.11 billion, an increase of 21.61% compared to ¥914.68 million in 2020[127]. - The net increase in cash and cash equivalents was -¥79.10 million, a significant decrease of 193.23% compared to -¥26.97 million in 2020[127]. - The company's cash and cash equivalents at the end of 2021 were approximately ¥97.41 million, down from ¥213.69 million at the beginning of the year, a decrease of 3.77% in total asset proportion[133]. - The company has enhanced its financial management to address risks related to foreign exchange fluctuations and increasing accounts receivable and inventory levels[175].

Financial Performance - Revenue for Q3 2021 reached ¥259,391,381.67, an increase of 59.19% compared to the same period last year[3] - Net profit attributable to shareholders was ¥27,972,041.45, representing a 128.97% increase year-on-year[3] - Year-to-date revenue totaled ¥712,251,076.35, up 60.56% from the previous year[3] - Basic earnings per share for Q3 2021 was ¥0.05, a 150.00% increase compared to the same period last year[3] - The company achieved a total operating revenue of CNY 712.25 million in the third quarter of 2021, representing a year-on-year growth of 60.56%[16] - The net profit attributable to shareholders of the listed company was CNY 87.60 million, an increase of 32.61% compared to the same period last year[16] - Operating profit rose to CNY 344.83 million, a 137.63% increase, attributed to higher sales and effective cost control[11] - Net profit for the current period was ¥95,049,013.36, representing a 43.9% increase from ¥66,056,817.03 in the previous period[31] - The company reported a comprehensive income total of ¥91,668,573.14, compared to ¥56,840,848.10 in the prior period, indicating a growth of 61.4%[32] - Basic and diluted earnings per share increased to ¥0.15 from ¥0.12, reflecting a growth of 25%[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,006,545,738.98, a decrease of 4.93% from the end of the previous year[4] - The company's total assets decreased to approximately 3.01 billion RMB as of September 30, 2021, down from 3.16 billion RMB at the end of 2020[29] - The company's total liabilities decreased to approximately 1.13 billion RMB as of September 30, 2021, compared to 1.35 billion RMB at the end of 2020[28] - The total liabilities and equity combined amounted to CNY 3,162,557,184.02, ensuring a balanced financial structure[40] - Total liabilities amounted to CNY 793,348,737.63, with current liabilities at CNY 640,019,844.31[43] - Non-current liabilities totaled CNY 153,328,893.32, including deferred income of CNY 126,511,306.31 and deferred tax liabilities of CNY 26,817,587.01[43] Cash Flow - Cash flow from operating activities for the year-to-date was ¥178,920,160.92, down 25.13% compared to the previous year[3] - The net cash flow from operating activities was CNY 76.51 million, a decrease of 32.05% due to increased payments for raw materials[12] - The company reported a total net cash flow from financing activities of CNY -132.60 million, a decline of 234.90% due to reduced new bank loans[12] - Cash flow from operating activities generated a net cash inflow of ¥178,920,160.92, down from ¥238,987,217.42 in the previous period[34] - Cash and cash equivalents at the end of the period decreased to ¥119,043,168.43 from ¥250,440,957.13, a decline of 52.4%[35] - Investment activities resulted in a net cash outflow of ¥68,835,831.99, compared to a larger outflow of ¥257,181,034.45 in the previous period[34] - Financing activities led to a net cash outflow of ¥132,599,755.34, contrasting with a net inflow of ¥98,296,408.34 in the prior period[35] Research and Development - Research and development expenses increased by 175.61% year-on-year, amounting to ¥25,206,415.86[10] - Research and development expenses increased by 152.20% to CNY 10.09 million, indicating a significant investment in innovation[11] - The company has increased its R&D expenses to ¥25,206,415.86, up from ¥9,145,527.03, marking a rise of 175.5%[30] Market and Business Strategy - The company reported a significant increase in plant extraction revenue, contributing to the overall revenue growth[10] - Revenue from the plant extraction business reached CNY 691.12 million, up 76.70% year-on-year, driven by the rising demand for natural sweeteners[16] - The natural sweetener segment generated CNY 417.97 million in revenue, reflecting a 55.08% increase year-on-year, benefiting from the "sugar-free" trend[16] - The company plans to continue expanding its market presence and investing in new product development[10] - The company plans to enhance its natural sweetener business through a non-public offering to solidify its position as a leading global producer[16] - The company is actively expanding its natural sweetener business through collaboration with Firmenich, focusing on product sales, technical exchanges, and customer development[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,308[14] - The company received approval from the China Securities Regulatory Commission for a non-public offering of up to 165,470,085 shares, valid for 12 months from the approval date[18] Inventory and Other Assets - The company’s inventory decreased to approximately 507.40 million RMB as of September 30, 2021, from 691.31 million RMB at the end of 2020[25] - The company holds inventory valued at CNY 691,314,076.95, indicating a significant asset base[38] - The company has a long-term investment of CNY 423,634,326.45, indicating strategic growth initiatives[42] Audit Status - The third quarter report for 2021 was not audited, indicating a lack of external verification for the financial data presented[44]

桂林莱茵生物科技股份有限公司 2021 年半年度报告全文 桂林莱茵生物科技股份有限公司 2021 年半年度报告 2021 年 08 月 1 桂林莱茵生物科技股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及公司未来计划等前瞻性陈述，公司声明该计划不构成公司对 投资者的实质承诺，请投资者及相关人士对此保持足够的风险认识，理解计划、 预测与承诺之间的差异。 本公司敬请广大投资者认真阅读本报告，并特别注意公司存在的宏观经济 风险、管理风险、财务风险、疫情加剧导致经营环境恶化的风险等，详细内容 见本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措施"中阐 述的公司可能面对的风险因素。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2021-031 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，桂林莱茵生物科技股份有限公司（以下 简称"公司"）将参加由广西上市公司协会、深圳市全景网络有限公司共同举办 的"2021年广西地区上市公司投资者网上集体接待日活动"，现将有关事项公告 如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·投资者关系互动平台"网站（http：//ir.p5w.net）参 与公司本次投资者集体接待日活动，活动时间为2021年5月21日（星期五）15:30 至17:00。 届时公司副总经理兼董事会秘书罗华阳先生、财务总监郑辉女士、独立董事 连漪先生将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况、 融资情况和可持续发展等投资者关注的问题进行交流。期间，公司高管将全程在 线，通过全景网投资者关系互动平台实时回答投资者的提问。 欢迎广大投资者积极参与。 特此公告。 桂林莱茵生物科技股份有限公司董事会 二 ...

桂林莱茵生物科技股份有限公司 2021 年第一季度报告全文 桂林莱茵生物科技股份有限公司 2021 年第一季度报告 2021 年 04 月 1 桂林莱茵生物科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证季度报告中财务报表的真实、准确、完整。 2 桂林莱茵生物科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 221,038,586.19 | 116,978,083.20 | 88.96% | | 归属于上市公司股东的净利润（元） | 21,533,458.97 | ...

桂林莱茵生物科技股份有限公司 2020 年年度报告全文 桂林莱茵生物科技股份有限公司 2020 年年度报告 2021 年 03 月 1 桂林莱茵生物科技股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管 人员)张为鹏声明：保证本年度报告中财务报告的真实、准确、完整。 年度报告中涉及公司未来计划等前瞻性的陈述，能否实现取决于市场状况 变化等多种因素，存在不确定性，并不代表公司对未来年度的盈利预测，也不 构成公司对投资者的实质承诺，投资者及相关人士应对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。敬请投资者注意投资风险。 本公司敬请广大投资者认真阅读本年度报告全文，并特别注意公司存在的 政策风险、宏观经济风险、行业风险、原材料采购风险、汇率变动风险等，详 细内容见本年度报告"第四节 经营情况讨论与分析"之"九、公司未来发展的展 望"中阐述的公司可能面对的风险因素 ...